title: 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
abstract: Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date. However, concerns about the pharmacokinetic liabilities of the hydroxamic acid moiety have stimulated research efforts aimed at finding alternative nonhydroxamate ZBGs. We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition. 3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively. Remarkably, 3-HPT gives no inhibition of HDAC 1. Subsequent optimization led to several novel 3HPT-based HDACi that are selective for HDAC 6 and HDAC 8. Furthermore, a subset of these inhibitors induces apoptosis in various cancer cell lines.
authors.affiliation: School of Chemistry and Biochemistry, Georgia Institute of Technology , Atlanta, Georgia 30332-0400, United States.
authors.forename: Vishal
authors.initials: V
authors.lastname: Patil
authors.forename: Quaovi H
authors.initials: QH
authors.lastname: Sodji
authors.forename: James R
authors.initials: JR
authors.lastname: Kornacki
authors.forename: Milan
authors.initials: M
authors.lastname: Mrksich
authors.forename: Adegboyega K
authors.initials: AK
authors.lastname: Oyelere
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D006655:Histone Deacetylases / Q000737:chemistry* / Q000378:metabolism*; D006801:Humans; D042541:Intracellular Space / Q000187:drug effects / Q000378:metabolism; D062105:Molecular Docking Simulation; D011487:Protein Conformation; D011725:Pyridines / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D011728:Pyridones / Q000378:metabolism / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D013871:Thiones / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D015032:Zinc / Q000378:metabolism*
chemical_list: D056572:Histone Deacetylase Inhibitors; D011725:Pyridines; D011728:Pyridones; D013871:Thiones; C091598:3-hydroxypyridin-2-one; D006655:Histone Deacetylases; D015032:Zinc
references.citation: Cancer Lett. 2009 Aug 8;280(2):168-76
references.pmid: 19103471
references.citation: Curr Top Med Chem. 2009;9(3):272-91
references.pmid: 19355991
references.citation: Clin Cancer Res. 2006 Sep 1;12(17):5199-206
references.pmid: 16951239
references.citation: Eur J Med Chem. 2005 Jan;40(1):1-13
references.pmid: 15642405
references.citation: Biochem J. 2008 Jan 15;409(2):581-9
references.pmid: 17868033
references.citation: Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7
references.pmid: 12419380
references.citation: Curr Med Chem. 2004 Nov;11(22):2911-77
references.pmid: 15544483
references.citation: Curr Med Chem. 2005;12(24):2867-80
references.pmid: 16305476
references.citation: J Antibiot (Tokyo). 2011 Sep;64(9):635-44
references.pmid: 21811259
references.citation: J Med Chem. 2009 Jan 22;52(2):456-68
references.pmid: 19093884
references.citation: Cell. 1999 Aug 6;98(3):285-94
references.pmid: 10458604
references.citation: Bioorg Med Chem. 2010 Jan 1;18(1):415-25
references.pmid: 19914074
references.citation: J Am Chem Soc. 2004 Jul 14;126(27):8388-9
references.pmid: 15237990
references.citation: ChemMedChem. 2007 Feb;2(2):152-71
references.pmid: 17163561
references.citation: Dalton Trans. 2005 Aug 7;(15):2588-96
references.pmid: 16025179
references.citation: Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20003-8
references.pmid: 21037108
references.citation: J Med Chem. 2010 Aug 26;53(16):6100-11
references.pmid: 20669972
references.citation: J Am Chem Soc. 2010 Aug 11;132(31):10842-6
references.pmid: 20614936
references.citation: Nature. 1997 Sep 25;389(6649):349-52
references.pmid: 9311776
references.citation: Structure. 2004 Jul;12(7):1325-34
references.pmid: 15242608
references.citation: Bioorg Med Chem Lett. 2004 Jul 5;14(13):3389-95
references.pmid: 15177439
references.citation: ACS Comb Sci. 2011 Jul 11;13(4):347-50
references.pmid: 21639106
references.citation: Nature. 1999 Sep 9;401(6749):188-93
references.pmid: 10490031
references.citation: Science. 2002 Mar 29;295(5564):2387-92
references.pmid: 11923519
references.citation: Trends Neurosci. 2009 Nov;32(11):591-601
references.pmid: 19775759
references.citation: Curr Drug Metab. 2008 Nov;9(9):879-85
references.pmid: 18991584
references.citation: Hypertension. 2010 Sep;56(3):437-44
references.pmid: 20679181
references.citation: J Med Chem. 2003 Nov 20;46(24):5097-116
references.pmid: 14613312
references.citation: Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
references.pmid: 11259830
references.citation: Adv Drug Deliv Rev. 2002 Mar 31;54(3):273-89
references.pmid: 11922948
references.citation: J Biol Inorg Chem. 2004 Apr;9(3):307-15
references.pmid: 14762707
references.citation: Biochemistry. 2008 Jun 10;47(23):6242-50
references.pmid: 18470998
references.citation: Gene. 2005 Dec 19;363:15-23
references.pmid: 16289629
references.citation: Nat Rev Genet. 2007 Apr;8(4):286-98
references.pmid: 17339880
references.citation: J Med Chem. 2012 Feb 23;55(4):1465-77
references.pmid: 22260166
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7
references.pmid: 10200307
references.citation: Future Med Chem. 2012 Mar;4(4):505-24
references.pmid: 22416777
references.citation: Leukemia. 2008 May;22(5):1026-34
references.pmid: 18256683
references.citation: J Inorg Biochem. 2000 Apr;79(1-4):47-51
references.pmid: 10830846
references.citation: Chem Rev. 1999 Sep 8;99(9):2735-76
references.pmid: 11749499